INFO & CONTACTS:  +39 02 2390 1

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Del Vecchio Michele

Main Facility: Oncologia medica melanomi

Drug: EIK1001

Pathologies: Melanoma

Randomized clinical study aimed at evaluating the safety, efficacy, and optimal dose of the investigational drug EIK1001 in combination with pembrolizumab in patients with advanced oncological disease.

The study is divided into two parts: an initial dose optimization phase and a subsequent Phase 2/3 confirmatory phase.In the first phase, patients are randomly assigned to three groups: one group receives placebo in combination with pembrolizumab, while the other two groups receive EIK1001 at different dose levels (0.60 mg/m² or 0.75 mg/m²), both in combination with pembrolizumab. 

Treatment is administered once weekly until Week 27 and then once every three weeks thereafter.In the second phase, patients receive either placebo or the selected dose of EIK1001 identified in the first phase, always in combination with pembrolizumab, following the same dosing schedule.

Last update: 09/06/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe